Literature DB >> 2374070

Neurodynamics of relapse prevention: a neuronutrient approach to outpatient DUI offenders.

R J Brown1, K Blum, M C Trachtenberg.   

Abstract

The central nervous system rewarding properties of ethanol, cocaine, and heroin may activate a common catecholaminergic reward system in the mesolimbic circuitry of the brain. Driving-under-the-influence (DUI) offenders with either alcohol- or cocaine-related problems were studied. The neuronutrients SAAVE and Tropamine significantly reduced relapse rates and enhanced recovery in these DUI outpatient offenders over a 10-week period. Follow-up on both the SAAVE and Tropamine groups after 10 months revealed a 73% and a 53% overall recovery rate, respectively. These clinical results favor the use of these neuronutrients as adjuncts to psychological therapeutic modalities.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2374070     DOI： 10.1080/02791072.1990.10472542

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN： 0279-1072


  17 in total

1.  Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial.

Authors:  K Blum; M Febo; R D Badgaiyan
Journal:  Austin Addict Sci       Date:  2016-10-12

2.  Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).

Authors:  Kenneth Blum; Marcelo Febo; Lyle Fried; Mona Li; Kristina Dushaj; Eric R Braverman; Thomas McLaughlin; Bruce Steinberg; Rajendra D Badgaiyan
Journal:  Subst Use Misuse       Date:  2016-12-29       Impact factor: 2.164

Review 3.  Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children?

Authors:  Mark S Gold; Kenneth Blum; Marlene Oscar-Berman; Eric R Braverman
Journal:  Postgrad Med       Date:  2014-01       Impact factor: 3.840

4.  Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation.

Authors:  Kenneth Blum; Mark S Brodie; Subhash C Pandey; Jean Lud Cadet; Ashim Gupta; Igor Elman; Panayotis K Thanos; Marjorie C Gondre-Lewis; David Baron; Shan Kazmi; Abdalla Bowirrat; Marcelo Febo; Rajendra D Badgaiyan; Eric R Braverman; Catherine A Dennen; Mark S Gold
Journal:  J Pers Med       Date:  2022-06-20

5.  Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD).

Authors:  Kenneth Blum; Margaret A Madigan; Lyle Fried; Eric R Braverman; John Giordano; Rajendra D Badgaiyan
Journal:  Glob J Addict Rehabil Med       Date:  2017-02-23

6.  Early intervention of intravenous KB220IV--neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study.

Authors:  Merlene Miller; Amanda L C Chen; Stan D Stokes; Susan Silverman; Abdalla Bowirrat; Matthew Manka; Debra Manka; David K Miller; Kenneth Perrine; Thomas J H Chen; John A Bailey; William Downs; Roger L Waite; Margaret A Madigan; Eric R Braverman; Uma Damle; Mallory Kerner; John Giordano; Siobhan Morse; Marlene Oscar-Berman; Debmalya Barh; Kenneth Blum
Journal:  J Psychoactive Drugs       Date:  2012 Nov-Dec

Review 7.  Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Authors:  Kenneth Blum; Thomas J H Chen; B William Downs; Abdalla Bowirrat; Roger L Waite; Eric R Braverman; Margaret Madigan; Marlene Oscar-Berman; Nicholas DiNubile; Eric Stice; John Giordano; Siobhan Morse; Mark Gold
Journal:  Postgrad Med       Date:  2009-11       Impact factor: 3.840

8.  Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Elizabeth Stuller; David Miller; John Giordano; Siobhan Morse; Lee McCormick; William B Downs; Roger L Waite; Debmalya Barh; Dennis Neal; Eric R Braverman; Raquel Lohmann; Joan Borsten; Mary Hauser; David Han; Yijun Liu; Manya Helman; Thomas Simpatico
Journal:  J Addict Res Ther       Date:  2012-11-27

9.  Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note.

Authors:  Kenneth Blum; Marlene Oscar-Berman; John Femino; Roger L Waite; Lisa Benya; John Giordano; Joan Borsten; William B Downs; Eric R Braverman; Raquel Loehmann; Kristina Dushaj; David Han; Thomas Simpatico; Mary Hauser; Debmalya Barh; Thomas McLaughlin
Journal:  J Addict Res Ther       Date:  2013-04-23

Review 10.  Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.

Authors:  Kenneth Blum; Amanda Lih Chuan Chen; Thomas J H Chen; Eric R Braverman; Jeffrey Reinking; Seth H Blum; Kimberly Cassel; Bernard W Downs; Roger L Waite; Lonna Williams; Thomas J Prihoda; Mallory M Kerner; Tomas Palomo; David E Comings; Howard Tung; Patrick Rhoades; Marlene Oscar-Berman
Journal:  Theor Biol Med Model       Date:  2008-11-12       Impact factor: 2.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.